血管生成抑制剂治疗脑胶质母细胞瘤的研究进展  

Progress in the treatment of glioblastoma with angiogenesis inhibitors

作　　者：张俊杰(综述) 段虎斌(审校)[1] ZHANG Jun-jie;DUAN Hu-bin(Department of Neurosurgery,First Hospital of Shanxi Medical University,Taiyuan 030001,Shanxi,CHINA)

机构地区：[1]山西医科大学第一医院神经外科,山西太原030001

出　　处：《海南医学》2023年第12期1807-1810,共4页Hainan Medical Journal

基　　金：山西省人社厅留学人员科技活动择优资助项目(编号:晋人社厅函【2021】479、20210020);山西省高等学校教学改革创新项目(编号:J20220329)。

摘　　要：胶质母细胞瘤(glioblastoma,GBM)是成人中枢神经系统(central nervous system,CNS)恶性程度最高的脑肿瘤,其主要特征包括巨噬细胞主导的免疫抑制和高度的血管化。近二十年来,多种血管生成因子和相关基因已被证实与胶质母细胞瘤血管生成关系密切,进一步的临床研究发现使用血管生成抑制因子和药物抑制胶质母细胞瘤的增殖具有临床可行性,抗血管生成治疗也成为继手术、放化疗、生物疗法之后治疗胶质母细胞瘤的一种新方法。本文概述了以贝伐单抗为代表的血管生成抑制剂治疗胶质母细胞瘤的历史与现状,并针对其耐药性等临床困境进行讨论。Glioblastoma(GBM)is the most malignant brain tumor in the central nervous system(CNS)of adults.Its main features include macrophage-dominated immunosuppression and high vascularization.In the last two decades,a variety of angiogenic factors and genes have been confirmed to be closely related to the angiogenesis of glioblastoma.Further clinical research found that it is clinically feasible to use angiogenesis inhibitors and drugs to inhibit the proliferation of glioblastoma.Anti-angiogenesis therapy has also become a new method to treat glioblastoma after surgery,radiotherapy,chemotherapy,and biological therapy.In this paper,the history and present situation of angiogenesis inhibitors,such as bevacizumab,in the treatment of glioblastoma are summarized,and the clinical difficulties such as drug resistance are discussed.

关 键 词：胶质母细胞瘤 抗血管生成 贝伐单抗 恶性进展 治疗 

分 类 号：R739.41[医药卫生—肿瘤]